Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals landed a collaborative agreement with Royal Philips (NYSE:PHG) sleep and respiratory care subsidiary Philips Respironics. The agreement covers Philips’ iNeb aerosol drug delivery device and Mast’s lead product candidate, AIR001, a sodium nitrite solution for intermittent inhalation.
The iNeb system is a portable, small vibrating mesh technology nebulizer that is delivers more reproducible doses of medication faster than ultrasonic nebulizers, according to Philips.
Get the full story at our sister site, Drug Delivery Business News.
The post Mast Therapeutics inks deal with Philips Respironics for iNeb aerosol delivery device appeared first on MassDevice.
from MassDevice http://ift.tt/2e08uWx
Cap comentari:
Publica un comentari a l'entrada